SARS-CoV-2 detection with aptamer-functionalized gold nanoparticles

Aithal, Srivatsa; Mishriki, Sarah; Gupta, Rohit; Sahu, Rakesh P.; Botos, George; Tanvir, Shazia; Hanson, Russell W.; Puri, Ishwar K.

doi:10.1016/j.talanta.2021.122841

Cited by 56 publications

(49 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 51 In another work, the use of aptamer-functionalized gold nanoparticles was reported, achieving a detection limit of 10 nM, which is equivalent to 3540 genome copies/μL of inactivated SARS-CoV-2. 67 Using a 44-mer G-quadruplex-forming DNA aptamer they selected against the spike trimer antigen of SARS-CoV-2, Gupta et al achieved a detection limit of 2 nM. 52 They used this aptamer for the analysis of 232 NP samples, achieving a highly discriminatory response between SARS-CoV-2-infected individuals from the noninfected ones with a sensitivity and specificity of 91 and 98%, respectively.…”

Section: Resultsmentioning

confidence: 99%

Aptamer Sandwich Assay for the Detection of SARS-CoV-2 Spike Protein Antigen

et al. 2021

View full text Add to dashboard Cite

The novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) emerged at the end of 2019, resulting in the ongoing COVID-19 pandemic. The high transmissibility of the virus and the substantial number of asymptomatic individuals have led to an exponential rise in infections worldwide, urgently requiring global containment strategies. Reverse transcription-polymerase chain reaction is the gold standard for the detection of SARS-CoV-2 infections. Antigen tests, targeting the spike (S) or nucleocapsid (N) viral proteins, are considered as complementary tools. Despite their shortcomings in terms of sensitivity and specificity, antigen tests could be deployed for the detection of potentially contagious individuals with high viral loads. In this work, we sought to develop a sandwich aptamer-based assay for the detection of the S protein of SARS-CoV-2. A detailed study on the binding properties of aptamers to the receptor-binding domain of the S protein in search of aptamer pairs forming a sandwich is presented. Screening of aptamer pairs and optimization of assay conditions led to the development of a laboratory-based sandwich assay able to detect 21 ng/mL (270 pM) of the protein with negligible cross-reactivity with the other known human coronaviruses. The detection of 375 pg of the protein in viral transport medium demonstrates the compatibility of the assay with clinical specimens. Finally, successful detection of the S antigen in nasopharyngeal swab samples collected from suspected patients further establishes the suitability of the assay for screening purposes as a complementary tool to assist in the control of the pandemic.

show abstract

Section: Resultsmentioning

confidence: 99%

Aptamer Sandwich Assay for the Detection of SARS-CoV-2 Spike Protein Antigen

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Another study used antigen-coated Au NPs through the principle of plasmon resonance to assist in the detection of the N protein of SARS-CoV-2 [ 213 ]. Au NPs could be also used as nanoprobes to detect the S protein of SARS-CoV-2 [ 214 ].…”

Section: Np Delivery—a Platform Ensuring the Efficacy And Stability O...mentioning

confidence: 99%

Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract

Zhang

Almazi

Ong

et al. 2022

IJMS

View full text Add to dashboard Cite

Since December 2019, a pandemic of COVID-19 disease, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread across the globe. At present, the Food and Drug Administration (FDA) has issued emergency approval for the use of some antiviral drugs. However, these drugs still have limitations in the specific treatment of COVID-19, and as such, new treatment strategies urgently need to be developed. RNA-interference-based gene therapy provides a tractable target for antiviral treatment. Ensuring cell-specific targeted delivery is important to the success of gene therapy. The use of nanoparticles (NPs) as carriers for the delivery of small interfering RNA (siRNAs) to specific tissues or organs of the human body could play a crucial role in the specific therapy of severe respiratory infections, such as COVID-19. In this review, we describe a variety of novel nanocarriers, such as lipid NPs, star polymer NPs, and glycogen NPs, and summarize the pre-clinical/clinical progress of these nanoparticle platforms in siRNA delivery. We also discuss the application of various NP-capsulated siRNA as therapeutics for SARS-CoV-2 infection, the challenges with targeting these therapeutics to local delivery in the lung, and various inhalation devices used for therapeutic administration. We also discuss currently available animal models that are used for preclinical assessment of RNA-interference-based gene therapy. Advances in this field have the potential for antiviral treatments of COVID-19 disease and could be adapted to treat a range of respiratory diseases.

show abstract

“…According to statistics, compared with a single PCR test, the positive detection rate is significantly increased from 51.9 % to 98.6 % by combining the PCR with the ELISA assay for each patient [ 116 ]. Srivatsa et al used aptamer-functionalized gold nanoparticles to identify SARS-CoV-2 spike proteins, limit of detection can up to 3540 genome copies/μl [ 117 ]. However, the cross-reactivity and low antibodies titers are among common factors that limited the detection efficacy of ELISA.…”

Section: Detection Mechanism Of Sars-cov-2mentioning

confidence: 99%

Micro/nano biomedical devices for point-of-care diagnosis of infectious respiratory diseases

Wang

Dong

et al. 2022

Medicine in Novel Technology and Devices

View full text Add to dashboard Cite

Corona Virus Disease 2019 (COVID-19) has developed into a global pandemic in the last two years, causing significant impacts on our daily life in many countries. Rapid and accurate detection of COVID-19 is of great importance to both treatments and pandemic management. Till now, a variety of point-of-care testing (POCT) approaches devices, including nucleic acid-based test and immunological detection, have been developed and some of them has been rapidly ruled out for clinical diagnosis of COVID-19 due to the requirement of mass testing. In this review, we provide a summary and commentary on the methods and biomedical devices innovated or renovated for the quick and early diagnosis of COVID-19. In particular, some of micro and nano devices with miniaturized structures, showing outstanding analytical performances such as ultra-sensitivity, rapidness, accuracy and low cost, are discussed in this paper. We also provide our insights on the further implementation of biomedical devices using advanced micro and nano technologies to meet the demand of point-of-care diagnosis and home testing to facilitate pandemic management. In general, our paper provides a comprehensive overview of the latest advances on the POCT device for diagnosis of COVID-19, which may provide insightful knowledge for researcher to further develop novel diagnostic technologies for rapid and on-site detection of pathogens including SARS-CoV-2.

show abstract

SARS-CoV-2 detection with aptamer-functionalized gold nanoparticles

Cited by 56 publications

References 45 publications

Aptamer Sandwich Assay for the Detection of SARS-CoV-2 Spike Protein Antigen

Aptamer Sandwich Assay for the Detection of SARS-CoV-2 Spike Protein Antigen

Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract

Micro/nano biomedical devices for point-of-care diagnosis of infectious respiratory diseases

Contact Info

Product

Resources

About